Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder

2021 ◽  
Vol 53 ◽  
pp. 49-78
Author(s):  
Elizabeth Schneider ◽  
Suzanne Higgs ◽  
Colin T. Dourish
2008 ◽  
Vol 9 (2) ◽  
pp. 129-136 ◽  
Author(s):  
Sérgio Carlos Stefano ◽  
Josué Bacaltchuk ◽  
Sérgio Luís Blay ◽  
José Carlos Appolinário

2020 ◽  
Vol 11 ◽  
Author(s):  
Maria Elisa Gisbert Cury ◽  
Arthur Berberian ◽  
Bruno Sini Scarpato ◽  
Jess Kerr-Gaffney ◽  
Flavia H. Santos ◽  
...  

2021 ◽  
Vol 11 (9) ◽  
pp. 931
Author(s):  
Natalia Rozakou-Soumalia ◽  
Ştefana Dârvariu ◽  
Jan Magnus Sjögren

Emotion dysregulation is a transdiagnostic phenomenon in Eating Disorders (ED), and Dialectical Behaviour Therapy (DBT) (which was developed for reducing dysregulated emotions in personality disorders) has been employed in patients with ED. This systematic review and meta-analysis investigated whether the effect of DBT was stronger on emotion dysregulation, general psychopathology, and Body Mass Index (BMI) in participants with ED, when compared to a control group (active therapy and waitlist). Eleven studies were identified in a systematic search in accordance with PRISMA guidelines. Most studies included participants with Binge Eating Disorder (BED) (n = 8), some with Bulimia Nervosa (BN) (n = 3), and only one with Anorexia Nervosa (AN). The pooled effect of DBT indicated a greater improvement in Emotion Regulation (ER) (g = −0.69, p = 0.01), depressive symptoms (g = −0.33, p < 0.00001), ED psychopathology (MD = −0.90, p = 0.005), Objective Binge Episodes (OBE) (MD = −0.27, p = 0.003), and BMI (MD = −1.93, p = 0.01) compared to the control group. No improvement was detected in eating ER following DBT (p = 0.41). DBT demonstrated greater efficacy compared with the control group in improving emotion dysregulation, ED psychopathology, and BMI in ED. The limitations included the small number of studies and high variability.


CNS Spectrums ◽  
2020 ◽  
pp. 1-9 ◽  
Author(s):  
Mikail Nourredine ◽  
Lucie Jurek ◽  
Marine Auffret ◽  
Sylvain Iceta ◽  
Guillaume Grenet ◽  
...  

Abstract Background. To assess the efficacy and safety of topiramate in treating binge eating disorder (BED), using a systematic review and meta-analysis of the available randomized clinical trials (RCTs). Methods. The RCTs assessing topiramate vs placebo with or without adjunctive psychotherapy in BED were reviewed using a systematic search in the PubMed, Web of Science, PsycINFO, Cochrane Database of Systematic Review, and ClinicalTrials.gov search Websites, from inception to November 2019. Main outcomes were the changes in binge frequency, quality of life, and weight, respectively. Effect estimates were pooled using random-effect models and presented as risk ratios (RRs) or mean differences (MDs) and their 95% confidence interval (95% CI). Data extraction was performed by two independent reviewers. Results. Three studies were eligible for inclusion, involving 528 BED patients. Topiramate was found to be significantly more efficacious than placebo in reducing: (a) the number of binge episodes per week (MD = −1.31; 95% CI = −2.58 to −0.03; I2 = 94%); (b) the number of binge days per week (MD = −0.98; 95% CI = −1.80 to −0.16; I2 = 94%); and (c) weight (MD = −4.91 kg; 95% CI = −6.42 to −3.41; I2 = 10%). However, participants in the topiramate groups withdrew significantly more frequently for safety reasons, relative to placebo participants (RR = 1.90; 95% CI = 1.13-3.18, I2 = 0%). Conclusions. Preliminary findings support a possible efficacy of topiramate for the treatment of BED, even if safety concerns could limit the practical use of this treatment in BED subjects.


Sign in / Sign up

Export Citation Format

Share Document